Skip to main content
. 2022 Feb 11;14(4):896. doi: 10.3390/cancers14040896

Figure 5.

Figure 5

Forest plots of progression-free survival (PFS, (a)) and overall survival (OS, (b)), according to categorized patient characteristics. Hazard ratios and 95% CL of an earlier progression or an earlier death for ‘morning’ vs. ‘afternoon’ nivolumab groups.